BioDelivery Sciences International, Inc. (BDSI) Financial Statements (2025 and earlier)

Company Profile

Business Address 4131 PARKLAKE AVENUE
RALEIGH, NC 27612
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments111,58463,88843,82221,19532,01983,560
Cash and cash equivalents111,58463,88843,82221,19532,01983,560
Receivables48,15038,79013,6278,8523,5692,488
Inventory, net of allowances, customer advances and progress billings17,44311,3125,4066,0913,3682,558
Inventory17,44311,3125,4066,0913,3682,558
Other undisclosed current assets5,2083,7693,1883,6104,1363,933
Total current assets:182,385117,75966,04339,74843,09292,539
Noncurrent Assets
Operating lease, right-of-use asset471720
Property, plant and equipment  2,0753,0723,7784,2304,262
Intangible assets, net (including goodwill)56,0912,7623,4184,0755,0005,971
Goodwill2,7152,7152,7152,7152,7152,715
Intangible assets, net (excluding goodwill)53,376477031,3602,2853,256
Deferred income tax assets  
Other undisclosed noncurrent assets94759,58936,00040,500  
Total noncurrent assets:57,50965,14642,49048,3539,23010,233
TOTAL ASSETS:239,894182,905108,53388,10152,322102,772
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:52,99553,99321,53926,14918,17419,501
Employee-related liabilities5,4885,5453,8143,4722,0521,917
Accounts payable4,21311,7043,16612,2369,39710,177
Accrued liabilities36,22830,49112,9926,7654,6253,488
Other undisclosed accounts payable and accrued liabilities7,0666,2531,5673,6762,1003,919
Debt     6,707
Deferred revenue and credits 1,7161,875
Total current liabilities:52,99553,99321,53926,14919,89028,083
Noncurrent Liabilities
Long-term debt and lease obligation78,45258,56851,65247,66029,27222,168
Long-term debt, excluding current maturities78,45258,56851,65247,66029,27222,168
Liabilities, other than long-term debt2135805,6005,41520,82520,825
Deferred revenue and credits 20,00020,000
Other liabilities2135805,6005,415825825
Total noncurrent liabilities:78,66559,14857,25253,07550,09742,993
Total liabilities:131,660113,14178,79179,22469,98771,076
Equity
Equity, attributable to parent108,23469,76429,7428,877(17,665)31,696
Preferred stock  22222
Common stock1049671565453
Treasury stock, value(252)(47)(47)(47)(47)(47)
Additional paid in capital449,264436,306381,004313,922292,667274,891
Accumulated deficit(340,882)(366,593)(351,288)(305,056)(310,341)(243,203)
Total equity:108,23469,76429,7428,877(17,665)31,696
TOTAL LIABILITIES AND EQUITY:239,894182,905108,53388,10152,322102,772

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues156,471111,38955,64061,98515,54648,231
Revenue, net61,18614,41247,322
Cost of revenue(24,665)(21,590)(15,783)(19,496)(11,258)(8,101)
Cost of goods and services sold(24,665)(21,590)(15,783)(443)(10)(60)
Gross profit:131,80689,79939,85742,4894,28840,130
Operating expenses(98,827)(86,063)(63,505)(71,909)(68,223)(75,309)
Operating income (loss):32,9793,736(23,648)(29,420)(63,935)(35,179)
Nonoperating income (expense)(3)4(14)27,3106425
Investment income, nonoperating    27,336  
Other nonoperating income (expense)(3)4(14)(26)6425
Interest and debt expense  (19,040)(10,192)(8,577)(3,267)(2,518)
Income (loss) from continuing operations before equity method investments, income taxes:32,976(15,300)(33,854)(10,687)(67,138)(37,672)
Other undisclosed loss from continuing operations before income taxes(7,013)     
Income (loss) from continuing operations before income taxes:25,963(15,300)(33,854)(10,687)(67,138)(37,672)
Income tax expense (benefit)(252)(5)(13)15,972  
Income (loss) from continuing operations:25,711(15,305)(33,867)5,285(67,138)(37,672)
Income (loss) before gain (loss) on sale of properties:25,711(15,305)(33,867)5,285(67,138)(37,672)
Net income (loss) attributable to parent:25,711(15,305)(33,867)5,285(67,138)(37,672)
Preferred stock dividends and other adjustments   (12,500)   
Net income (loss) available to common stockholders, diluted:25,711(15,305)(46,367)5,285(67,138)(37,672)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):25,711(15,305)(33,867)5,285(67,138)(37,672)
Comprehensive income (loss), net of tax, attributable to parent:25,711(15,305)(33,867)5,285(67,138)(37,672)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: